Pharma readings

By Miguel Tovar | Miguel Tovar created a magazine on Flipboard. “Pharma readings on Flipboard” is available with thousands of other magazines and all the news you care about. Download Flipboard for free and search for “Miguel Tovar”.

Novartis's Rydapt wins EU approval for AML, other diseases

Reuters<p>By John Miller<p>ZURICH, Sept 20 (Reuters) - Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a …

Cancer

Alnylam's genetic disease drug meets main goal in key study

Sept 20 (Reuters) - Alnylam Pharmaceuticals Inc said on Wednesday its drug met the main goal in a late-stage study in patients suffering from a life-threatening genetic disease.<p>The drug, patisiran, was being evaluated for the treatment of hereditary ATTR (hATTR) amyloidosis patients with …

Medicine

Former GSK CEO and ex-R&D boss move to biotech venture firms

LONDON (Reuters) - GlaxoSmithKline's (GSK.L) former chief executive Andrew Witty and its one-time research head Moncef Slaoui both picked up new jobs in the biotech venture capital sector on Tuesday, following a route favored by many ex-pharma executives.<p>Witty, who stepped down as head of Britain's …

Venture Capital

FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy

In 2016, Roche Holding AG sold $3 billion worth of its blockbuster biotechnology drug Avastin. Last week, the U.S. Food and Drug Administration …

Pharma

UK backs Opdivo for lung cancer after Bristol-Myers cuts price

LONDON (Reuters) - Bristol-Myers Squibb’s (BMY.N) immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain’s healthcare cost watchdog NICE after the drugmaker agreed a discounted price.<p>The National Institute for Health and Care Excellence (NICE) said on Wednesday …

Cancer

Teva Pharma to sell more women's health assets for $1.38 billion

TEL AVIV (Reuters) - Teva Pharmaceutical Industries Ltd (TEVA.N) (TEVA.TA) said on Monday it would sell the remaining assets in its specialty women’s health business for $1.38 billion in two separate transactions.<p>Israel-based Teva will use proceeds from these sales, along with those from its …

Women's Health

GlaxoSmithKline breathes easier as U.S. approves triple lung drug

LONDON (Reuters) - U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.<p>Trelegy Ellipta is the first once-daily triple …

Medicine

Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take

Bristol-Myers Squibb will pay Halozyme $105 million for the right to use the smaller company’s technology to develop easier-to-use versions of its best-selling cancer immunotherapy Opdivo, in addition to as many as 11 other drugs in the larger company’s research pipeline.<p>Halozyme’s technology uses …

Cancer

How Bacteria Could Protect Tumors From Anticancer Drugs

The success of a treatment might depend on a person’s microbes.<p>Cancers have unwitting allies: the healthy cells that surround them. Several groups of scientists have now found that normal cells can inadvertently release substances that shield their malignant neighbors from anticancer drugs. That …

Cancer

Pfizer, Astellas prostate cancer drug succeeds key trial

(Reuters) - Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease.<p>The drug, Xtandi, is already approved to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer …

Cancer

Pharma Keeps Ignoring Its Price Problem - Bloomberg Gadfly

Want to get pharma companies up in arms? Tell them it doesn't cost that much to get a cancer drug to market.<p>A widely reported paper published Monday …

Pharma

Novartis looks outside pharma for digital transformation

<b>Novartis has signalled its intention to change the way it approaches and uses technology, creating a new chief digital officer role and filling it</b> …

Pharma

Novartis scores but Roche misses in melanoma trials

Phase III trial combo success for Tafinlar/Mekinist “unprecedented”

Cancer

Doctors who take pharmaceutical money use Twitter to hype drugs

(Reuters Health) - Some cancer doctors use Twitter to promote drugs manufactured by companies that pay them, but they almost never disclose their conflicts of interest on the social media platform, a new study shows.<p>“This is a big problem,” said senior author Dr. Vinay Prasad, a professor at Oregon …

Medicine

AstraZeneca, Merck and Inctye boosted by cancer treatment advances

Investor hopes of making money from cutting-edge cancer treatments were given a boost on Monday with particularly positive data from UK-based …

Cancer

Lilly's abemaciclib data leaves potential uncertain

<b>One of Eli Lilly's most important pipeline prospects is breast cancer candidate abemaciclib, but new phase III data suggest the company could have</b> …

Cancer

New clinical trial might change the standard treatment for melanoma

In a head-to-head comparison of two immunotherapy drugs used to prevent relapse in certain patients with advanced melanoma, one treatment was the clear winner — and it's not the one that most people get.<p>The international study, released Sunday, involved 900 patients whose tumors were removed by …

Cancer

War on drugs: big pharma fights NHS bill curbs

With NHS budgets under pressure and medicine prices inexorably going up, something had to give.<p>Nevertheless, the decision by some of the world’s largest pharmaceutical firms this summer to challenge public sector powers to limit drug bills in the High Court still raised eyebrows.<p>The action brought …

Pharma

Why the Biosimilar Drug Revolution Hasn't Arrived

In a word: patents.<p>The Biologics Price Competition and Innovation Act was signed by President Barack Obama in 2010 as part of the Affordable Care Act. Its essential goal was to infuse competition and lower the prices of drugs that were made from living cells -- so-called biologics -- in much the …

Pharma

Departing Novartis CEO Sets His Eyes On Silicon Valley

The biggest surprise about Novartis Chief Executive Joe Jimenez’s departure on Monday was buried in the quote in the company’s press release where he talked about spending more time with his family. His family, he said, is “ready to return to Silicon Valley.”<p>With that simple clause, Jimenez, 57, …

Silicon Valley

Eli Lilly to cut 3,500 jobs, focus on developing new medicines

Eli Lilly said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which delayed development of a potential blockbuster …

Diabetes

STAT Plus: PhRMA’s Stephen Ubl talks pricing and politics  — and explains his reluctance to give Scott Gottlieb a grade

It seems like ages since President Trump castigated drug company executives for “getting away with murder” and promised to take on the powerful …

Scott Gottlieb

We May Soon Learn Just How Flexible Scott Gottlieb's FDA Is - Bloomberg Gadfly

One the FDA's biggest controversies is coming back to test its new leadership.<p>Sarepta Therapeutics Inc. on Wednesday released promising early data …

Medicine

New AstraZeneca, Amgen biotech drug offers broad asthma relief

LONDON (Reuters) - A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises to help a much broader range of patients than existing medicines like GlaxoSmithKline’s Nucala.<p>Findings from a mid-stage clinical trial involving 584 patients showed on Wednesday the …

Medicine

Bristol-Myers says FDA places partial hold on Opdivo myeloma trials

(Reuters) - The U.S. Food and Drug Administration has placed a partial hold on three clinical trials testing Bristol-Myers Squibb's immunotherapy Opdivo in combination with other medicines for multiple myeloma due to risks seen in similar studies involving a rival drug, the company said on …

Cancer

Personalized Cancer Vaccine Company Raises $93 Million

Venture funds seeded by drug giant Eli Lilly and search behemoth Alphabet are giving $92.7 million to a startup that aims to use machine learning to create personalized treatments for lung and stomach cancer. The deal is further evidence of the rich pools of private money that are feeding …

Cancer

EC approves for Merck's Keytruda for bladder cancer indication

New approval targets locally advanced or metastatic urothelial carcinoma

Cancer

IBM pitched Watson as a revolution in cancer care. It's nowhere close

This is a STAT Plus article and is only available to STAT Plus subscribers.<br>To read the full story, subscribe to STAT Plus or log in to your …

Cancer

AstraZeneca Chief Soriot Says He's Worried About Brexit Talks

AstraZeneca Plc Chief Executive Officer Pascal Soriot said he’s worried about the lack of progress in negotiations between the U.K. and the European …

Brexit